1
CRL Exam Study 226 Actual Exam
2026/2027 – Complete Exam-Style Questions
with Detailed Rationales | 100% Verified |
Pass Guaranteed – A+ Graded
[SECTION 1: ICH GCP Guidelines & Regulatory Framework — Questions 1-18]
Q1: According to the ICH E6(R2) Good Clinical Practice guideline, what is the primary
objective of GCP?
A. To ensure that the clinical trial is profitable for the sponsor.
B. To guarantee that the investigational product will be approved by the FDA.
C. To provide a unified standard for the design, conduct, recording, and reporting of clinical
trials that involve human subjects.
D. To reduce the cost of clinical research for the pharmaceutical industry.
Correct Answer: C
Rationale: The primary objective of ICH E6(R2) is to provide a unified standard that ensures the
rights, safety, and well-being of trial subjects are protected and that the clinical trial data are
credible, accurate, and reproducible. Profitability, guarantee of approval, and cost reduction are
not the stated goals of GCP standards; rather, the focus is on ethical conduct and scientific
validity.
Q2: Which of the following documents serves as a formal agreement between the FDA and the
sponsor regarding the manufacturing and clinical investigation of a new drug, and is required
before shipping the drug interstate for clinical trials?
A. Form FDA 1572
B. IND (Investigational New Drug Application)
C. IRB approval letter
D. Marketing Application (NDA/BLA)
Correct Answer: B
,2
Rationale: The IND is the exemption that allows a sponsor to ship a drug across state lines to
clinical investigators before FDA marketing approval. It contains information on the drug's
composition, manufacturing, and proposed clinical protocols. Form 1572 is a statement by the
investigator, and the NDA is submitted after trials are completed.
Q3: Which entity has the authority to approve a clinical trial protocol and ensure the protection
of human subjects at a specific institution or research site?
A. Sponsor
B. FDA
C. Institutional Review Board (IRB) / Independent Ethics Committee (IEC)
D. Institutional Review Board (IRB) / Independent Ethics Committee (IEC) [CORRECT]
D. Institutional Review Board (IRB) / Independent Ethics Committee (IEC)
Correct Answer: C
Rationale: The IRB (or IEC) is the independent body designated to review and approve the
initiation of a clinical trial to protect the rights and welfare of human subjects. While the FDA
oversees the IND application, the local IRB approval is mandatory for the study to begin at a
specific site. The sponsor funds the study but does not grant ethical approval.
Q4: Which federal regulation governs electronic signatures and electronic records in clinical
trials, ensuring that electronic systems are valid and equivalent to paper records?
A. 21 CFR Part 11
B. 21 CFR Part 50
C. 21 CFR Part 312
D. 45 CFR Part 46
Correct Answer: A
Rationale: 21 CFR Part 11 defines the criteria under which the FDA considers electronic records,
electronic signatures, and handwritten signatures executed to electronic records to be
trustworthy, reliable, and generally equivalent to paper records. Part 50 covers Informed
Consent, Part 312 covers INDs, and 45 CFR 46 is the Common Rule for human subjects
protection.
,3
Q5: What is the specific title of the document that an investigator signs to commit to following
the protocol, conducting the trial in compliance with GCP, and supervising the trial staff?
A. Confidentiality Agreement
B. Contract
C. FDA Form 1572 (Statement of Investigator)
D. Curriculum Vitae (CV)
Correct Answer: C
Rationale: FDA Form 1572 is required for drug investigations and represents the investigator's
commitment to conduct the study according to the protocol, FDA regulations, and GCP
guidelines. It also outlines the investigator's credentials and site resources. A CV is a resume of
education, and a Contract is a legal agreement between site and sponsor regarding payment.
Q6: According to the Declaration of Helsinki, what is the obligation of the medical doctor when
the potential benefits of a clinical trial are not proven to outweigh the risks?
A. The doctor may proceed if the patient is willing to take the risk.
B. The doctor must obtain approval from the sponsor only.
C. The doctor must abstain from initiating the trial.
D. The doctor should consult the media for public opinion.
Correct Answer: C
Rationale: The Declaration of Helsinki states that in medical research involving human subjects,
the well-being of the individual research subject must take precedence over all other interests;
therefore, if risks outweigh benefits, the trial should not be initiated. Patient willingness alone is
not sufficient if the risk/benefit ratio is unfavorable.
Q7: The Belmont Report outlines three basic ethical principles for research involving human
subjects. Which of the following is NOT one of them?
A. Respect for Persons
B. Beneficence
C. Justice
D. Confidentiality
, 4
Correct Answer: D
Rationale: The three principles of the Belmont Report are Respect for Persons (autonomy),
Beneficence (do no harm, maximize benefits), and Justice (fair distribution of research burdens
and benefits). Confidentiality is a critical component of privacy and HIPAA, but it is not one of
the three overarching principles defined in the Belmont Report.
Q8: What distinguishes 21 CFR Part 312 (Drugs) from 21 CFR Part 812 (Devices)?
A. Part 312 deals with medical devices, while Part 812 deals with pharmaceuticals.
B. Part 312 governs the use of investigational new drugs, while Part 812 governs the use of
investigational devices.
C. Part 312 requires an IDE, while Part 812 requires an IND.
D. Part 312 is regulated by the FTC, while Part 812 is regulated by the FDA.
Correct Answer: B
Rationale: Part 312 establishes the procedures for conducting clinical trials with investigational
drugs (IND), whereas Part 812 establishes the procedures for clinical trials with investigational
devices (IDE). The acronyms are specific to their respective product types, and both are FDA
regulations.
Q9: According to ICH E6(R2), what is the definition of "Essential Documents"?
A. Documents that allow the FDA to audit the site.
B. Documents which individually and collectively permit evaluation of the conduct of a trial and
the quality of the data produced.
C. Documents that are expensive to produce and therefore essential to keep safe.
D. Documents signed only by the Principal Investigator.
Correct Answer: B
Rationale: Essential Documents are defined as documents that individually and collectively
permit the evaluation of the conduct of a trial and the quality of the data produced. They serve to
demonstrate the investigator's compliance with GCP and regulatory requirements. They are not
defined by cost or signatory alone.
CRL Exam Study 226 Actual Exam
2026/2027 – Complete Exam-Style Questions
with Detailed Rationales | 100% Verified |
Pass Guaranteed – A+ Graded
[SECTION 1: ICH GCP Guidelines & Regulatory Framework — Questions 1-18]
Q1: According to the ICH E6(R2) Good Clinical Practice guideline, what is the primary
objective of GCP?
A. To ensure that the clinical trial is profitable for the sponsor.
B. To guarantee that the investigational product will be approved by the FDA.
C. To provide a unified standard for the design, conduct, recording, and reporting of clinical
trials that involve human subjects.
D. To reduce the cost of clinical research for the pharmaceutical industry.
Correct Answer: C
Rationale: The primary objective of ICH E6(R2) is to provide a unified standard that ensures the
rights, safety, and well-being of trial subjects are protected and that the clinical trial data are
credible, accurate, and reproducible. Profitability, guarantee of approval, and cost reduction are
not the stated goals of GCP standards; rather, the focus is on ethical conduct and scientific
validity.
Q2: Which of the following documents serves as a formal agreement between the FDA and the
sponsor regarding the manufacturing and clinical investigation of a new drug, and is required
before shipping the drug interstate for clinical trials?
A. Form FDA 1572
B. IND (Investigational New Drug Application)
C. IRB approval letter
D. Marketing Application (NDA/BLA)
Correct Answer: B
,2
Rationale: The IND is the exemption that allows a sponsor to ship a drug across state lines to
clinical investigators before FDA marketing approval. It contains information on the drug's
composition, manufacturing, and proposed clinical protocols. Form 1572 is a statement by the
investigator, and the NDA is submitted after trials are completed.
Q3: Which entity has the authority to approve a clinical trial protocol and ensure the protection
of human subjects at a specific institution or research site?
A. Sponsor
B. FDA
C. Institutional Review Board (IRB) / Independent Ethics Committee (IEC)
D. Institutional Review Board (IRB) / Independent Ethics Committee (IEC) [CORRECT]
D. Institutional Review Board (IRB) / Independent Ethics Committee (IEC)
Correct Answer: C
Rationale: The IRB (or IEC) is the independent body designated to review and approve the
initiation of a clinical trial to protect the rights and welfare of human subjects. While the FDA
oversees the IND application, the local IRB approval is mandatory for the study to begin at a
specific site. The sponsor funds the study but does not grant ethical approval.
Q4: Which federal regulation governs electronic signatures and electronic records in clinical
trials, ensuring that electronic systems are valid and equivalent to paper records?
A. 21 CFR Part 11
B. 21 CFR Part 50
C. 21 CFR Part 312
D. 45 CFR Part 46
Correct Answer: A
Rationale: 21 CFR Part 11 defines the criteria under which the FDA considers electronic records,
electronic signatures, and handwritten signatures executed to electronic records to be
trustworthy, reliable, and generally equivalent to paper records. Part 50 covers Informed
Consent, Part 312 covers INDs, and 45 CFR 46 is the Common Rule for human subjects
protection.
,3
Q5: What is the specific title of the document that an investigator signs to commit to following
the protocol, conducting the trial in compliance with GCP, and supervising the trial staff?
A. Confidentiality Agreement
B. Contract
C. FDA Form 1572 (Statement of Investigator)
D. Curriculum Vitae (CV)
Correct Answer: C
Rationale: FDA Form 1572 is required for drug investigations and represents the investigator's
commitment to conduct the study according to the protocol, FDA regulations, and GCP
guidelines. It also outlines the investigator's credentials and site resources. A CV is a resume of
education, and a Contract is a legal agreement between site and sponsor regarding payment.
Q6: According to the Declaration of Helsinki, what is the obligation of the medical doctor when
the potential benefits of a clinical trial are not proven to outweigh the risks?
A. The doctor may proceed if the patient is willing to take the risk.
B. The doctor must obtain approval from the sponsor only.
C. The doctor must abstain from initiating the trial.
D. The doctor should consult the media for public opinion.
Correct Answer: C
Rationale: The Declaration of Helsinki states that in medical research involving human subjects,
the well-being of the individual research subject must take precedence over all other interests;
therefore, if risks outweigh benefits, the trial should not be initiated. Patient willingness alone is
not sufficient if the risk/benefit ratio is unfavorable.
Q7: The Belmont Report outlines three basic ethical principles for research involving human
subjects. Which of the following is NOT one of them?
A. Respect for Persons
B. Beneficence
C. Justice
D. Confidentiality
, 4
Correct Answer: D
Rationale: The three principles of the Belmont Report are Respect for Persons (autonomy),
Beneficence (do no harm, maximize benefits), and Justice (fair distribution of research burdens
and benefits). Confidentiality is a critical component of privacy and HIPAA, but it is not one of
the three overarching principles defined in the Belmont Report.
Q8: What distinguishes 21 CFR Part 312 (Drugs) from 21 CFR Part 812 (Devices)?
A. Part 312 deals with medical devices, while Part 812 deals with pharmaceuticals.
B. Part 312 governs the use of investigational new drugs, while Part 812 governs the use of
investigational devices.
C. Part 312 requires an IDE, while Part 812 requires an IND.
D. Part 312 is regulated by the FTC, while Part 812 is regulated by the FDA.
Correct Answer: B
Rationale: Part 312 establishes the procedures for conducting clinical trials with investigational
drugs (IND), whereas Part 812 establishes the procedures for clinical trials with investigational
devices (IDE). The acronyms are specific to their respective product types, and both are FDA
regulations.
Q9: According to ICH E6(R2), what is the definition of "Essential Documents"?
A. Documents that allow the FDA to audit the site.
B. Documents which individually and collectively permit evaluation of the conduct of a trial and
the quality of the data produced.
C. Documents that are expensive to produce and therefore essential to keep safe.
D. Documents signed only by the Principal Investigator.
Correct Answer: B
Rationale: Essential Documents are defined as documents that individually and collectively
permit the evaluation of the conduct of a trial and the quality of the data produced. They serve to
demonstrate the investigator's compliance with GCP and regulatory requirements. They are not
defined by cost or signatory alone.
